populations more likely to be diagnosed with metastatic disease. These findings may have implications for future screening and treatment strategies, especially given the increasing rates of cervical adenocarcinoma. doi:10.1016/j.ygyno.2019.04.292 1444 - Poster Session Cardiovascular comorbidities and risk of ovarian carcinoma among African American women in the African American cancer epidemiology study (AACES) J.N. Staples a , L.C. Peres b , F. Camacho a , A.J. Alberg c , E. Bandera d , J. Barnholtz-Sloan e , M.L. Bondy f , M.L. Cote g , E. Funkhouser h , P.G. Moorman i , E.S. Peters j , A.G. Schwartz k , P.D. Terry l , J.M. Schildkraut a . a University of Virginia, Charlottesville, VA, USA, b Moffitt Cancer Center- University of South Florida, Tampa, FL, USA, c Medical University of South Carolina, Charleston, SC, USA, d UMDNJ-The Cancer Institute of New Jersey, New Brunswick, NJ, USA, e Case Western Reserve - MacDonald Women's Hospital, Cleveland, OH, USA, f Baylor College of Medicine, Houston, TX, USA, g Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA, h University of Alabama at Birmingham, Birmingham, AL, USA, i Duke University School of Medicine, Durham, NC, USA, j Woman's Hospital, LSU Health Sciences Center, Baton Rouge, LA, USA, k Wayne State University, Detroit, MI, USA, l University of Tennessee Health Science Center, Memphis, TN, USA Objective: Studies that have examined the association between cardiovascular comorbid conditions and epithelial ovarian cancer (EOC) have yielded inconsistent results. It remains unknown whether cardiometabolic disease is associated with EOC in African- American women, who generally have a higher prevalence of cardiovascular disease and lower risk of EOC, yet poorer survival than European-American women. Here, we estimate the effect of cardiovascular comorbid conditions and EOC risk among African- American women. Method: Data were available from 593 ovarian carcinoma patients and 752 controls enrolled in the African-American Cancer Epidemi- ology Study (AACES). During the baseline telephone questionnaire, participants were asked to self-report a history of hypertension, hyperlipidemia, and diabetes and any current medication use. The relationship between hypertension, hyperlipidemia, diabetes, and medications taken for these conditions was determined using multivariate logistic regression, with adjustment for appropriate confounders. Results: While hypertension was associated with a 30% increased EOC risk (OR = 1.32, 95% CI 1.01–1.73), use of antihypertensive medications among hypertensive women was associated with a decreased risk compared to never users (OR = 0.43, 95% CI 0.28– 0.66). In particular, use of diuretics, angiotensin receptor blockers, and ace inhibitors were individually associated with a decreased risk (OR = 0.52, 95% CI 0.37–0.72; OR = 0.50, 95% CI 0.34– 0.74; and OR = 0.57, 95% CI 0.40–0.82, respectively). Use of calcium channel blockers or beta blockers was not associated with risk. History of hyperlipidemia or diabetes was associated with a decreased EOC risk, with ORs of 0.61 (95% CI 0.47–0.80) and 0.67 (95% CI 0.49–0.91), respectively. In the overall sample, never use of any oral antidiabetes medication decreased the risk of EOC, particularly among the Biguanide drug class (OR = 0.63, 95% CI 0.43–0.93). Similarly, a decreased risk was observed for use of statins (OR = 0.55, 95% CI 0.41–0.73). Conclusion: Our results provide evidence that hypertension is associated with an increased risk of EOC among African-American women, while diabetes and hyperlipidemia are associated with reduced risk, potentially driven by use of particular medications. doi:10.1016/j.ygyno.2019.04.293 1445 - Poster Session Disparities in extent of surgical cytoreduction for patients with ovarian cancer D.H. Wong a , A.L. Mardock a , T. Lai b , Y. Sanaiha b , A.K. Sinno b , P. Benharash b , J.G. Cohen b . a UCLA David Geffen School of Medicine, Los Angeles, CA, USA, b University of California, Los Angeles, Los Angeles, CA, USA Objective: To achieve complete surgical cytoreduction in ovarian cancer, tumor debulking with extended procedures beyond hyster- ectomy and bilateral salpingo-oophorectomy are often needed. This study examines disparities in patients receiving extended cytoreduction in relation to hospital surgical volume. Method: A retrospective study using the National Inpatient Sample was conducted. Women diagnosed with ovarian, fallopian tube, or primary peritoneal cancer who underwent surgery involving oophorectomy from 2011 to 2015 were analyzed. Survey weights were applied to produce a national estimate. Surgical volume was determined by grouping hospitals into quartiles based on the number of cases they performed annually. Extended cytoreduction was defined as surgery of the colon, small intestine, liver, diaphragm, spleen, gastric resection, ileostomy, or colostomy. χ 2 univariate analysis identified differences in demographics between patients who underwent extended cytoreduction and those who did not. Logistic regression assessed independent predictors for receiving extended cytoreduction. Results: Of the estimated 79,913 patients undergoing surgery for ovarian, fallopian tube, and primary peritoneal cancer, 49,288 (61.7%) received extended cytoreduction. Patients more likely to receive extended cytoreduction were the following: white (71.8% vs 69.9%, Table 1 Independent predictors of receiving extended surgical cytoreduction in patients with ovarian, fallopian tube, and primary peritoneal cancer. Odds Ratio [95% CI] P-value Age 60-69 0.82 [0.71- 0.96] 0.013 70-79 0.69 [0.58- 0.82] b0.001 80+ 0.49 [0.40- 0.60] b0.001 Elixhauser comorbidity score 1 1.57 [1.31- 1.88] b0.001 2 1.42 [1.20- 1.69] b0.001 3+ 1.18 [1.00- 1.39] 0.049 Race Black 0.76 [0.66- 0.86] b0.001 Hispanic 0.78 [0.68- 0.90] b0.001 Primary payer Medicaid 0.79 [0.70- 0.89] b0.001 Medicare 0.89 [0.80- 0.98] 0.022 ZIP income quartile Q3 1.20 [1.09- 1.33] b0.001 Q4 (highest) 1.24 [1.11- 1.38] b0.001 Hospital geographic region Midwest 1.30 [1.12- 1.50] b0.001 Patient Disposition at Discharge Home Health 1.45 [1.29- 1.62] b0.001 Hospital ovarian cancer surgery volume quartile Q2 1.16 [1.05- 1.29] 0.004 Q3 1.39 [1.24- 1.56] b0.001 Q4 (highest) 1.28 [1.12- 1.47] b0.001 0090-8258/$ – see front matter Abstracts / Gynecologic Oncology 154 (2019) 2–288 123